Study on Allopregnanolone and Depression in Women Across the Menopause Transition
ConditionDepression
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age40-60
SponsorBeth Israel Deaconess Medical Center
About this trial
This study aims to identify how enhanced allopregnanolone activity (via pregnenolone) affects behavior and neurobiology that may underlie perimenopausal depression.
Eligibility criteria
Qualifiers
Healthy women ages 40 to 60 years in the menopause transition
Depressive symptoms
Psychotropic medications are allowed if the dose is stable prior to screening and throughout the study
Able to read Arabic numerals and perform simple arithmetic
Disqualifiers
Systemic hormone therapy
Contraindicated medications with pregnenolone
Systemic corticosteroid
Other psychiatric illnesses that are considered to be primary
Trial design
Treatments tested in this trial
- pregnenolone
- placebo
Treatment groups
80 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov